Entries by admin_senzagen

SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

Lund, September 18, 2018 – SenzaGen (Nasdaq First North: SENZA) announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary GARD® technology platform. Using genetic biomarkers, GARDair tests whether substances and chemicals that are inhaled or come into contact with the lungs are allergenic or not, with high accuracy. 

Senzagen lanserar det första in vitro testet för luftvägsallergier – GARDair – på ESTIV2018

Lund, 18 september 2018 – SenzaGen (Nasdaq First North: SENZA) meddelar idag att Bolaget lanserar GARDair som är det första in vitro testet för luftvägsallergier på ESTIV2018, the 20th International Congress on In Vitro Toxicology. Genom att GARDair, som bygger på företagets patentskyddade teknikplattform GARD®, undanröjer behovet av djurförsök, öppnas ett helt nytt marknadssegment. Med hjälp av genetiska biomarkörer testar GARDair, med hög noggrannhet, om substanser och kemikalier som andas in eller som kommer i kontakt med lungorna är allergiframkallande eller inte.

ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

Lund, September 18, 2018 – SenzaGen (Nasdaq First North: SENZA) has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year. The authority cites high workload as reason for the delay. Instead, ECVAM has announced that the evaluation of GARDskin is now scheduled for an extra meeting to be held during spring 2019. 

SenzaGen targets the growing medical device market

Lund, August 29, 2018 – SenzaGen (Nasdaq First North: SENZA) announces today that the Company is now expanding its market focus to the medical device market. This market is in strong growth as a result of a growing and aging population in combination with a new regulatory framework for medical devices and increased quality standards.